tirzepatide hfpef At #ACC25, Dr. Milton Packer and colleagues present a new secondary analysis from the SUMMIT trial evaluating the effect of in patients with obesity, #HFpEF, and CKD. The trial demonstrated that # tirzepatide jama JAMA: Semaglutide and

Description

This is complemented by markers for inflammation and stress, such as cortisol and DHEA-S, which provide information about stress, recovery, and inflammatory processes

However, the associations between GLP-1RAs and bulimia nervosa or PTSD were based solely on evidence from Mendelian randomization analysis

Ekterly: The First Orally Administered On-Demand HAE Treatment Autologous Chimeric Antigen Receptor CAR T cell Immunotherapy Risk Evaluation and Mitigation Strategies Removed Early Tirofiban Intervention Lowers Likelihood of Disability Post-Stroke Obicetrapib in High Risk Patients: A New Chapter in Cholesterol Management Lorundrostat for Uncontrolled Hypertension: Phase 3 Clinical Trial The Potential of Cagrilintide/Semaglutide (CagriSema) in Weight Management The Unfortunate Link Between GLP-1 RAs and Neovascular Macular Degeneration Efsitora: A New Approach to Insulin for Type Two Diabetics Maintaining Potassium Homeostasis: Potential Hidden Perk of SGLT2is Upadacitinib: A Promising Advance in Giant-Cell Arteritis Management FDAs Commissioners National Priority Voucher: A New Approach to Strategic Drug Development Potential Liver Indication for SGLT2 Inhibitors Unexpected Protection: How the Meningococcal Vaccine May Prevent Gonorrhea Beyond Monoamines: Exploring KV7 Channel Modulator Azetukalner in MDD Limertinib: A Promising First-Line Treatment for Non-Small Cell Lung Cancer Camizestrant Outperforms Aromatase Inhibitors in ESR1-Mutated ER+/HER2- Advanced Breast Cancer: A Phase 3 SERENA-6 Study Pacific RxTracts - July 2025 Pacific RxTracts Articles: First Blood Test Approved For the Diagnosis of Alzheimers Disease Rare Withdrawal Reaction Prompts Label Update for Common Antihistamines FDA Approves SUSVIMO: Shifting Diabetic Retinopathy Treatment from Monthly Injections to Continuous Therapy Battle Against Resistant Hypertension Two Is Better than One: Obicetrapib and Ezetimibe, a Novel Combination Pill for High Cholesterol Histo-blood Group ABO System Transferase and Venous Thromboembolism Risk GLP-1 Agonists and Thiazolidinedione Combination Therapy in Type 2 Diabetes Dual Pathway Targeting in Type 2 Diabetes: Exploring the Synergy of GLP1- RAs and SGLT2-inhibitors Two Vaccines, One Shot: Combined Immunizations Against COVID-19 and Influenza Mirikizumab: A New Frontier in Ulcerative Colitis Treatment Tocilizumab: A Better Way to Manage Rheumatoid Arthritis Oveporexton: A Novel Treatment Option for Narcolepsy Type I The Long-Term Effects of Ketamine on Treatment- Resistant Depression The First Targeted Therapy for a Rare Ovarian Cancer Vimseltinib Gains FDA Approval for Tenosynovial Giant Cell Tumour (TGCT) Hot Flashes No More Remote Clinical Pharmacists Drive Down Cancer Care Costs in Value-Based Model Camizestrant Takes Victory Lap After Phase 3 Trials Pacific RxTracts - June 2025 Pacific RxTracts Articles: Atzumi Receives FDA Approval as First Nasal Powder DHE for Migraine Treatment IMAAVY: First and Only FDA-approved Neonatal Fc Receptor Inhibitor for gMG New Prophylactic Treatment Approved for Hemophilia A or B, With or Without Factor Inhibitors Cytisinicline: The Next Smoking Cessation Aid FDA Approves Dupilumab for the Management of Chronic Spontaneous Urticaria Study Shows Promise in Combining Behavioral Treatment with Phentermine Metformin for Osteoarthritis A New Direction in Atopic Dermatitis Treatment Orforglipron: A Potential Oral Alternative to Injectable GLP-1 Agonists Beyond GLP-1s: MariTides Dual Mechanism in Weight Loss Therapy Atrasentan Gains FDA Approval to Combat Proteinuria in Primary IgA Nephropathy Fluoroquinolones and Increased Risk of Suicide

Food and Drug Administration (FDA) for weight loss management and the treatment of moderate to severe obstructive sleep apnea (OSA) in individuals with obesity